Lupus Profundus Treatment in Pregnancy or Breastfeeding
Active lupus profundus in a patient who is pregnant or breastfeeding requires a carefully selected treatment approach that accounts for the specific demands of this clinical context.
Clinical Scenario
This protocol covers active lupus profundus occurring during pregnancy or while breastfeeding — a situation that directly shapes which treatments are appropriate and how they are managed.
Treatment Approach
The structured regimen for this scenario involves dapsone as the therapeutic agent. The complete protocol — including dosing guidance, sequencing, and monitoring — is available in full via the link below.
References
In active disease during pregnancy or breastfeeding, we recommend HCQ as first line treatment for CLE at usual dosage.
In active disease or during flares, we suggest dapsone for HCQ-refractory CLE patients as an alternative treatment in during pregnancy or breastfeeding.
We recommend to start dapsone with a low dose treatment (50 mg/day) and to increase it to a maximum of 1.5 mg/kg according to clinical response and side-effects.